Amir Reichman - Jan 1, 2023 Form 3 Insider Report for BiondVax Pharmaceuticals Ltd. (BVXV)

Role
Chief Executive Officer, Director
Signature
/s/ Amir Reichman
Stock symbol
BVXV
Transactions as of
Jan 1, 2023
Transactions value $
$0
Form type
3
Date filed
1/3/2023, 02:05 PM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BVXV Restricted Share Units Jan 1, 2023 Ordinary Shares 24M Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted share units were granted on March 2, 2021, and vest on an annual basis for a period of five years.
F2 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents four hundred Ordinary Shares.
F3 Each restricted share unit represents a contingent right to receive one ordinary share.